Recommendations for standardization of bleeding data analyses in contraceptive studies.


Journal

Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361

Informations de publication

Date de publication:
08 2022
Historique:
received: 28 01 2022
revised: 20 05 2022
accepted: 24 05 2022
pubmed: 1 6 2022
medline: 20 7 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

To address limitations that exist with existing definitions of menstrual bleeding changes that occur with contraceptive methods, we assembled a panel to develop new recommendations for standardization of bleeding data analyses associated with contraceptive use to better inform users, clinicians, investigators, pharmaceutical companies, and regulatory agencies. We propose three criteria for assessing bleeding outcomes: pattern, flow, and duration. The descriptors within each criterion depend on whether the contraceptive is designed to result in a predictable or unpredictable bleeding pattern. Predictable pattern outcomes quantify days of scheduled, unscheduled and no bleeding, while unpredictable pattern outcomes assess frequency. Flow is quantified based on patient comparisons to their typical flow when not using contraception, with spotting representing no menstrual products use. Duration of a prolonged bleeding and/or spotting episode is more than 7 days. Studies should assess bleeding characteristics for a minimum of 12 months for 21/7, 24/4, extended cycle or continuous regimens, two years for injectables, and the full duration of use for long-acting contraceptives. Describing pattern, flow and duration as independent categories allows a fuller understanding of the bleeding outcomes and better future assessments of acceptability and continuation. Standardization of outcomes permits better comparison between studies and data synthesis; standardization will also improve the ability of clinicians and patients to understand differences between products.

Identifiants

pubmed: 35640733
pii: S0010-7824(22)00152-4
doi: 10.1016/j.contraception.2022.05.011
pii:
doi:

Substances chimiques

Contraceptive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

14-22

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Mitchell D Creinin (MD)

Department of Obstetrics and Gynecology, University of California, Davis, Sacramento, CA, United States. Electronic address: mdcreinin@ucdavis.edu.

Carolina Sales Vieira (CS)

Department of Obstetrics and Gynecology, Ribeirao Preto Medical School, University of São Paulo, São Paulo, Brazil.

Carolyn L Westhoff (CL)

Department of Obstetrics and Gynecology, Columbia University, New York, NY, United States.

Diana J A Mansour (DJA)

Integrated Sexual Health Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH